Document is current
Any future updates will be listed below
-
Authors
Shover, Carolyn M.
Yan, Peter
Jackson, Nicholas J.
Buhr, Russell G.
Fulcher, Jennifer A.
Tashkin, Donald P.
Barjaktarevic, Igor https://orcid.org/0000-0002-8096-0858
-
Funding
Funding for this research was provided by:
UCLA Clinical and Translational Science Institute (UL1TR001881)
NIH/NCATS (KL2TR001882)
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 3 July 2022
First Online: 5 August 2022
Declarations
:
: This study was reviewed and approved by the UCLA Institutional Review Board (20-000473).
: RGB received personal consulting fees from Viatris/Theravance Biopharma, unrelated to this work. IZB reports consulting for Astra Zeneca, GSK, Viatris/Theravance, Aerogen, Verona Pharma and Grifols. Dr. Buhr is employed by the Veterans Health Administration. The views and findings of this manuscript do not necessarily reflect the opinions of the United States Government.
